---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017666"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T20:59:49.332938+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroBo appoints James P. Tursi, M.D. to Board effective Nov 1, 2023

## Summary
- Dr. Tursi brings 20 years pharma experience, currently EVP Global R&D at Endo International.
- He will serve on the Nominating and Corporate Governance Committee; receives initial 25,000 RSUs and $40k annual cash retainer.
- NeuroBo expects to file IND for DA-1726 (obesity) in coming months and start Phase 1a in H1 2024.
- DA-1241 (NASH) is in a Phase 2a trial; Dr. Tursi's expertise targets large cardiometabolic markets.
- Dr. Tursi's appointment strengthens board with deep R&D and regulatory background in drug development.

## SEC filing metadata
- accession: 0001558370-23-017666
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837023017666/0001558370-23-017666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837023017666/nrbo-20231101x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017666
- JSON: https://secwatch.observer/filing/0001558370-23-017666.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017666.txt

## Key facts
- Executive change
  James P. Tursi, M.D. was appointed as Director at MetaVia Inc..
  - Action: appointed
  - Role: Director
  source text: On November 1, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed James P. Tursi, M.D., effective immediately, to serve as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000155837023017666/0001558370-23-017666-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.